ACTU vs HRL · $49.0M cap vs P/E 29, rev $8.96B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Hormel Foods Corporation (HRL) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Hormel Foods Corporation (HRL) is a packaged foods company listed on NYSE.
ACTU does not have a complete income-statement cache yet.
Latest reported HRL revenue for 2026-07-26 was $8.96B. Net income was $398.8M. Revenue was up 49.4% from 2026-04-26 to 2026-07-26. HRL currently screens at market cap $13.39B and trailing P/E 28.6.
ACTU currently screens at market cap $49.0M. HRL currently screens at market cap $13.39B and trailing P/E 28.6.
Not investment advice. Open the ACTU and HRL stock pages for the full models.
Not investment advice.